NICE Technology Appraisal Guidance No 112 Hormonal therapies
for the adjuvant treatment of early oestrogen-receptor-positive
breast cancer
The above NICE appraisal has been considered by NHS Quality
Improvement Scotland through its revised
procedure of processing of NICE appraisals
Web Reference for Guidance and other related documents: http://www.nice.org.uk/guidance/TA112
NHSScotland should note that:
NHS Quality Improvement Scotland advises that this appraisal
supersedes the recommendations issued by the Scottish Medicines
Consortium on the use of anastrozole (6 October 2006) and letrozole
(7 April 2006). No important differences were identified for
exemestane (4 October 2005) and NHS Quality Improvement Scotland
advises that the recommendation is as valid for Scotland as for
England and Wales.
NHSScotland should take account of the NICE appraisal and this NHS
Quality Improvement Scotland email in its planning, funding and
provision of services to ensure that recommended drugs or
treatments are made available to meet clinical need.
NHS Quality Improvement Scotland advice represents the
evidence-based view of NHS Quality Improvement Scotland.
This advice does not override or replace the individual
responsibility of health professionals to make appropriate
decisions in the circumstances of their individual patients, in
consultation with the patient and/or guardian or carer.
No other publications on the NICE appraisal will be issued by NHS
Quality Improvement Scotland.
Hard copies of the NICE appraisals are available from NHS Quality
Improvement Scotland (contact Shonagh Buchanan, tel 0141 225 6993
or email shonagh.buchanan@nhshealthquality.org).
Published Date: 22 November 2006
